Form 4: Imunon Director Frederick J. Fritz Granted Stock Options

Director Frederick J. Fritz of Imunon, Inc. was granted stock options to purchase 3,750 shares of common stock at an exercise price of $0.8651 on March 14, 2025.

Summary

• On March 14, 2025, Frederick J. Fritz, a director of Imunon, Inc., was granted stock options.
• The options allow him to purchase 3,750 shares of Imunon's common stock at an exercise price of $0.8651 per share.
• The options vest in three tranches: 1/2 on the grant date, 1/4 on the one-year anniversary, and 1/4 on the two-year anniversary of the grant date.
• The options expire on March 14, 2035.
• A Power of Attorney was executed on March 17, 2025, granting Susan Eylward the authority to act on behalf of Frederick J. Fritz in matters related to SEC filings.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants, which is a standard practice. There are no indications of significant positive or negative implications.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company. This is a standard compensation practice.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead Sciences, and Biogen routinely grant stock options to their directors and officers.
• The vesting schedule and exercise price are generally determined based on the company's performance and industry benchmarks.
• The number of shares granted is relatively small, suggesting this is a standard grant for a director.

Stakeholder Impact

• The stock option grant could have a slightly positive impact on shareholder sentiment as it aligns the director's interests with the company's performance.

Key Dates